- Previous Close
16.83 - Open
16.83 - Bid 14.41 x 40000
- Ask 19.27 x --
- Day's Range
16.83 - 16.83 - 52 Week Range
16.83 - 24.35 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
828.374M - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
5.10 - EPS (TTM)
3.30 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.
www.towayakuhin.co.jp4,588
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TWAPF
View MorePerformance Overview: TWAPF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TWAPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TWAPF
View MoreValuation Measures
Market Cap
851.52M
Enterprise Value
2.18B
Trailing P/E
6.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.48
Price/Book (mrq)
0.72
Enterprise Value/Revenue
1.26
Enterprise Value/EBITDA
10.47
Financial Highlights
Profitability and Income Statement
Profit Margin
7.17%
Return on Assets (ttm)
2.84%
Return on Equity (ttm)
11.02%
Revenue (ttm)
235.95B
Net Income Avi to Common (ttm)
16.92B
Diluted EPS (ttm)
3.30
Balance Sheet and Cash Flow
Total Cash (mrq)
35.04B
Total Debt/Equity (mrq)
130.75%
Levered Free Cash Flow (ttm)
--